The US Food and Drug Administration has allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorised test for use with flow cytometry to aid in the detection of several leukaemias and lymphomas, including chronic leukaemia, acute leukaemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).

"This represents a major step forward for the haematology-oncology community," said Alberto Gutierrez, Ph.D., Director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

"Laboratories and health care professionals now have access to an FDA-validated test that provides consistent results to aid in the diagnoses of these serious cancers."

According to the National Cancer Institute, leukaemia is a cancer of the blood that originates in immature blood cells (also called leukocytes), which crowd out the healthy blood cells in the bone marrow.

Leukaemia occurs most often in adults older than 55 years, but it is also the most common cancer in children younger than 15 years.

Lymphoma is a cancer that begins in the cells of the lymph system, a part of the immune system that helps the body fight infection and disease.

The ClearLLab test is used to detect cancerous cells in blood, bone marrow and lymph nodes, and it also provides laboratories and clinicians with information about what type of leukaemia or lymphoma is present.

It works by marking proteins found on the surface of cells with fluorescent dyes for further analysis on an instrument known as a flow cytometer.

The FDA reviewed data for the ClearLLab test through the de novo premarket review pathway, a regulatory pathway for novel, low-to-moderate-risk devices that are not substantially equivalent to an already legally marketed device.

Its authorization was supported by a study designed to demonstrate the test's performance, which was conducted on 279 samples at four, independent clinical sites.

The study compared the test's results to alternative detection methods used by the clinical sites.

The study showed that the results of the test aligned with the study site's final diagnosis 93.4 percent of the time and correctly detected that there was a cancer presence (i.e., cancer abnormality) 84.2 percent of the time.

Along with this authorization, the FDA is establishing criteria, called special controls, which clarify the agency's expectations in assuring the test's accuracy, reliability and clinical relevance.

These special controls, when met along with general controls, provide reasonable assurance of safety and effectiveness for the ClearLLab Reagents and similar tests used to aid in the diagnosis of leukaemias and lymphomas.

The special controls also describe the least burdensome regulatory pathway for future developers of similar diagnostic tests for leukaemias and lymphomas.

Source: FDA